Cytovance Biologics Expands Services with In-House Formulation Development

Cytovance Biologics, a U.S.-based Contract Development and Manufacturing Organization (CDMO), has launched in-house formulation development services, reinforcing the company’s position as a full-service partner for biologic drug developers.

This expansion reflects Cytovance’s continued investment in innovation and commitment to delivering comprehensive solutions for complex development challenges. The new services are available to support existing and future client programs. 

“Our formulation development workflow is grounded in Quality by Design (QbD) principles to deliver speed, safety, and data-driven precision from the outset,” said Fuad Haddadin, Head of R&D at Cytovance Biologics. “Bringing formulation expertise in-house not only strengthens our technical capabilities but also reinforces our mission to deliver smarter, faster, and more reliable development paths for our clients.”

Axel Schleyer, Chief Commercial Officer of Cytovance Biologics, added, “It allows us to better serve our clients by accelerating development timelines and providing a truly integrated one-stop-shop approach, all while maintaining the highest standards of quality and regulatory compliance.”